לוקובורין טבע 10 מגמל ישראל - עברית - Ministry of Health

לוקובורין טבע 10 מגמל

abic marketing ltd, israel - calcium folinate - תמיסה להזרקה - calcium folinate 10.8 mg/ml - calcium folinate - calcium folinate - to diminish the toxicity and counteract the action of folic acid antagonists in cytotoxic therapy. as leucovorin-fluorouracil chemotherapy combination for cancer treatment.

קלציומפולינט אבווה 10 מגמל ישראל - עברית - Ministry of Health

קלציומפולינט אבווה 10 מגמל

novartis israel ltd - calcium folinate - תמיסה להזרקה - calcium folinate 10 mg/ml - calcium folinate - calcium folinate - to diminish the toxicity and counteract the action of the folic antagonists in cytotoxic therapy. as leukovorin-fluorouracil chemotherapy combination for cancer treatment.

לוקובורין טבע טבליות ישראל - עברית - Ministry of Health

לוקובורין טבע טבליות

teva israel ltd - calcium folinate - טבליה - calcium folinate 16.2 mg - detoxifying agents for antineoplastic treatment - counteracts the action of folic acid antagonists. improves blood picture in megaloblastic anemias due to folate deficiency. as leucovorin- fluorouracil combination chemotherapy in cancer.

לוקובורין 50 מ"ג ישראל - עברית - Ministry of Health

לוקובורין 50 מ"ג

salomon,levin & elstein ltd - calcium folinate 50 mg/vial - lyophilized powder for injection - calcium folinate - to diminish the toxicity and counteract the action of folic acid antagonists in cytotoxic therapy. as leucovorin- fluorouracil chemotherapy combinaton for cancer treatment.

לוקובורין ישראל - עברית - Ministry of Health

לוקובורין

abic ltd. - calcium folinate 15 mg - tablets - detoxifying agents for antineoplastic treatment - counteracts the action of folic acid antagonists. improves blood picture in megaloblastic anemias due to folate deficiency. as leucovorin- fluorouracil combination chemotherapy in cancer.

אקטוס 15 מג ישראל - עברית - Ministry of Health

אקטוס 15 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 15 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

אקטוס 30 מג ישראל - עברית - Ministry of Health

אקטוס 30 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 30 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

אקטוס 45 מג ישראל - עברית - Ministry of Health

אקטוס 45 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 45 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

אטקנד  4 מג ישראל - עברית - Ministry of Health

אטקנד 4 מג

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 4 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

אטקנד   8 מג ישראל - עברית - Ministry of Health

אטקנד 8 מג

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 8 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.